Biotechnology is defined as “the application of science and technology to living organisms as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services” (OECD, 2001). As it is seen in many fields, the change in biotechnology is directed in accordance with the change in human. The change in lifestyles and habits, prolongation of life span, change in the level of immunity and environmental factors necessitate the health biotechnology to be in constant change and innovation.

The urgent requirements in health services due to the increase in population can be fulfilled only when the investment in biotechnology increases and R&D projects leading to an end product are carried out. Consequently, as in other developed and developing countries, the budgets allocated to biotechnology R&D are showing an increase in Turkey each year. Approximately 1% of GDP was allocated to R&D expenses in Turkey in 2017.

Turkey has expanded its vision in health practices since the 2000s with the Health Transformation Program and has made significant progress to become a country that has a voice in the global arena. The scope of research infrastructures both in the public and private sectors and the ongoing research projects in Turkey show a strong correlation with the paths and approaches followed in health biotechnology worldwide.

Biotechnology will be the main theme of The 6th Turkish Medical World Congress, organized by Health Institutes of Turkey, this year. The focus points of the Congress will be:

● Metabolic Diseases,
● Precision Medicine,
● Drug Development,
● Vaccine Development,
● Production of Proteins and Chemicals.

The Congress will house foreign and local speakers who will not only present their academic work but will also share with us the most up-to-date information regarding the biotechnology industry.

Registration is required for those who would like to attend the Congress. Registration fee and further details will be announced later.
  • Organizing Committe

    Prof. Adil MARDİNOĞLU
    Health Institutes of Turkey, Director

    Prof. Hasan TÜRKEZ
    Health Institutes of Turkey, General Secretary

    Prof. İlhan SATMAN
    Health Institutes of Turkey, Director of Turkish Institute of Public Health and Chronic Diseases

    Prof. Adnane ACHOUR
    Karolinska Institute, Department of Medicine, Division for Infectious Diseases

    Prof. Aykut ÖZDARENDELİ
    Erciyes University, Vaccine Research and Development Application and Research Center

    Assoc. Prof. Kazım Yalçın ARĞA
    Marmara University, Faculty of Engineering, Department of Bioengineering

    Assoc. Prof. Mustafa GÜZEL
    İstanbul Medipol University, Faculty of Medicine, Department of Medical Pharmacology